ExGen Options Macrex Property in Alberni Mining District BC - ExGen Resources (OTC:BXXRF)

The White House Office of Trade and Manufacturing Policy released a 25-page report, “The Great Transshipment Scam,” alleging Chinese goods are transshipped through 40+ countries to evade U.S. tariffs. It estimates annual illegal transshipment at $40B to $303B, with Exiger’s central $75B (Feb 2025-Feb 2026). CBP will use Exiger’s “Detective Border” AI to score shipments before customs release, potentially holding or denying entry.

BlockchAIn Digital Infrastructure (AIB) announced a $1B+ lease strategy for its first data center development, anchored by Nebius. The 12-year lease includes 50 MW IT load, with initial construction expected in 10 months. The company plans to use customer prepayments and project-level debt for funding. AIB also has additional projects in Texas and other states, targeting 200-300 MW under contract by year-end.

Netflix laid off 1,000 employees, including top executives like Bela Bajaria, due to slow subscriber growth and content quality concerns. The company's release strategy and cancellation of shows have been criticized. New chief content officer Peter Rice is expected to improve content quality.

Posco's union announced an indefinite strike starting November 2 after wage talks failed. The union sought a 7.1% pay raise and a 600% bonus, while Posco offered 2.5% and a one-time payment. This follows earlier partial strikes. According to the union, negotiations collapsed due to disagreements on wage increases and other issues.

Moderna (MRNA) and Merck reported a 42% reduction in melanoma recurrence or death in a Phase 3 trial of Moderna's cancer vaccine. Shares fell 17.6% after data leaked early. The trial tested intismeran autogene with Merck's Keytruda. Moderna reported Q2 2026 loss of $782m on $145m revenue.

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.